VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors Jul 22, 2021
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update Jun 29, 2021
VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021 Jun 25, 2021
VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder May 26, 2021
VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer May 4, 2021
